Moderna : Further good progress
>Good progress, new ambitions - This R&D day was an opportunity for a recap on the company’s entire portfolio, which is still just as comprehensive (23 candidate therapies under development, 14 in clinical trials including 1 in phase III, 3 in phase II and 18 in phase I or preclinical trials).Moderna took advantage of the opportunity to present the preliminary results of the phase II trial in CytoMegaloVirus. This is the most advanced asset after MRNA1273 in SARS...Moderna is creating a new generation of medicines based on messenger RNA to improve the lives of patients. The company uses its platform to identify and develop new mRNA medicines. When the company identifies a combination of platform technologies or programs across mRNA technologies, delivery technologies, and manufacturing processes that can enable shared product features across multiple potential mRNA medicines, it groups those programs as a modality. The company has created six modalities including prohylactic vaccines; cancer vaccines; intratumoral immuno-oncology; localized regenerative therapeuctics; systemic secreted therapeutics; and systemic intracellular therapeutics.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.